Abstract
Background HHV8-positive diffuse large B-cell lymphoma, not otherwise specified (HDN) is a rare and aggressive lymphoma that usually arises in association with HHV8-positive multicentric Castleman disease. The epidemiology, treatment patterns and survival outcomes of HDN are poorly understood.
Methods A retrospective analysis was performed for 67 patients with HDN diagnosed from 2011 to 2020 using the SEER database. The clinicopathologic characteristics, treatment modalities and survival outcomes of HDN patients were evaluated. Kaplan-Meier analysis and Cox regression analysis were employed to identify prognostic factors for overall survival (OS) and disease-specific survival (DSS).
Results The median age at diagnosis was 51.8 years, and 79.1% of patients were male. The primary site distribution was mainly nodal (79.1%), while the extranodal sites were rarely involved (20.9%). The majority of patients were white (65.7%). Only 3.0% of patients received radiotherapy, while 55.2% received chemotherapy. The 1-year, 3-year and 5-year OS was 67.4%, 65.6%, 58.4%, and 56.3%, respectively, and the corresponding DSS was 73.1%, 73.1%, and 67.8%, respectively. The diagnosis year group of 2016-2020 had a significantly worse OS than the diagnosis year group of 2011-2015 (P = 0.040), but not for DSS (P = 0.074). No significant survival improvement was observed in patients underwent chemotherapy. Age and marital status were independent prognostic factors for OS, and age was an independent prognostic factor for DSS.
Conclusions HDN is a rare and aggressive disease, our study provides a comprehensive overview of the epidemiology, treatment patterns and survival outcomes of HDN patients for the first time. We revealed that older age and marital status of single were associated with worse survival of HDN, while chemotherapy was not associated with improved survival outcomes in HDN patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China, No. 82070174. The funder played no role in the design, conduct, or reporting of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
The data analyzed in this study are from the SEER database (https://seer.cancer.gov/) that are available to the public.
Abbreviations
- Chemo
- chemotherapy;
- CI
- confidence interval;
- COD
- cause of death;
- DSS
- disease-specific survival;
- HDN
- HHV8-positive diffuse large B-cell lymphoma, not otherwise specified;
- HR
- hazard ration;
- OS
- overall survival;
- RT
- radiation therapy;
- SEER
- Surveillance, Epidemiology, and End Results;
- SPMs
- second primary malignancies;
- NOS
- not otherwise specified.
